Since the mortality of CMT and SP10 patients is significantly lower than ALS, it is reasonable to speculate that the toxic aggregation of KIF5A might even contribute to the severity of the disease affecting individuals with C-terminal mutations in this gene. This evidence concerns the gene KIF5A and amyotrophic lateral sclerosis.